Search - tctmd.com

Displaying 41 - 57 of 57

Sort: Relevancy | Date

News Industry News

Study Finds That Prasugrel May Reduce Cardiovascular Events Among Patients Managed Medically After an Angiogram for Acute Coronary Syndrome

October 24, 2012

News Industry News

PROMUS Element™ and PROMUS Element™ Plus Receive CE Mark Approval for Labeling Update to Include Three-Month Dual Anti-Platelet Therapy

October 24, 2012

News Industry News

Analysis Of Medtronic Stent Finds Early Cessation Of Dual Antiplatelet Therapy Caused No Increased Risk Of Blood Clots To One Year

October 22, 2012

News Industry News

Revascularization with OrbusNeich’s Genous™ Stent May Enable the Safe and Early Discontinuation of Dual Antiplatelet Therapy for Patients with Increased Bleeding Risk

October 12, 2012

News Industry News

Abbott Announces CE Mark and European Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent

August 20, 2012

News Industry News

OrbusNeich's Genous™ Stent Is Safe and Effective in Patients Who Discontinue Dual Antiplatelet Therapy (DAPT) Within 15 Days of Stent Placement

June 21, 2012

News Industry News

Abbott's XIENCE PRIME™ and XIENCE V® Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy

May 15, 2012

News Industry News

OrbusNeich’s Combo Dual Therapy Stent™ Featured During Symposium at Angioplasty Summit TCTAP 2012

April 25, 2012

News Industry News

OrbusNeich’s Genous™ Stent Achieves Complete Endothelialization at Two Weeks

April 20, 2012

News Industry News

REMEDEE Study Meets Primary Endpoint: OrbusNeich’s Combo™ Dual Therapy Stent Is Non-Inferior to DES

November 13, 2011

News Industry News

OrbusNeich Introduces the Combo™ Dual Therapy Stent at TCT 2011

November 09, 2011

News Industry News

Risk of late stent thrombosis continues for up to seven years in patients with first generation drug-eluting stents; risk factors identified

November 08, 2011

News Industry News

Patients with ACS and/or diabetes who show poor response to dual antiplatelet therapy

November 08, 2011

News Industry News

Non-adherence to dual antiplatelet therapy following percutaneous coronary intervention results in higher rates of ischemic and bleeding events

November 08, 2011

News Industry News

Three-Year Clinical Outcomes from Use of GenousTM Stent in Large, Real-World Patient Population Demonstrate Long-Term Safety and Efficacy

November 07, 2011

News Industry News

Data Published in Circulation Journal Show OrbusNeich's GenousTM Stent Is Safe and Effective in Elderly Patients

October 25, 2011

News Industry News

OrbusNeich's GenousTM Stent Enables Early and Safe Discontinuation of Dual Antiplatelet Therapy in High-Risk Patients Requiring Nondeferrable, Non-Cardiac Surgery

July 18, 2011

Advertisement

Study Finds That Prasugrel May Reduce Cardiovascular Events Among Patients Managed Medically After an Angiogram for Acute Coronary Syndrome

PROMUS Element™ and PROMUS Element™ Plus Receive CE Mark Approval for Labeling Update to Include Three-Month Dual Anti-Platelet Therapy

Analysis Of Medtronic Stent Finds Early Cessation Of Dual Antiplatelet Therapy Caused No Increased Risk Of Blood Clots To One Year

Revascularization with OrbusNeich’s Genous™ Stent May Enable the Safe and Early Discontinuation of Dual Antiplatelet Therapy for Patients with Increased Bleeding Risk

Abbott Announces CE Mark and European Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent

OrbusNeich's Genous™ Stent Is Safe and Effective in Patients Who Discontinue Dual Antiplatelet Therapy (DAPT) Within 15 Days of Stent Placement

Abbott's XIENCE PRIME™ and XIENCE V® Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy

OrbusNeich’s Combo Dual Therapy Stent™ Featured During Symposium at Angioplasty Summit TCTAP 2012

OrbusNeich’s Genous™ Stent Achieves Complete Endothelialization at Two Weeks

REMEDEE Study Meets Primary Endpoint: OrbusNeich’s Combo™ Dual Therapy Stent Is Non-Inferior to DES

OrbusNeich Introduces the Combo™ Dual Therapy Stent at TCT 2011

Risk of late stent thrombosis continues for up to seven years in patients with first generation drug-eluting stents; risk factors identified

Patients with ACS and/or diabetes who show poor response to dual antiplatelet therapy

Non-adherence to dual antiplatelet therapy following percutaneous coronary intervention results in higher rates of ischemic and bleeding events

Three-Year Clinical Outcomes from Use of GenousTM Stent in Large, Real-World Patient Population Demonstrate Long-Term Safety and Efficacy

Data Published in Circulation Journal Show OrbusNeich's GenousTM Stent Is Safe and Effective in Elderly Patients

OrbusNeich's GenousTM Stent Enables Early and Safe Discontinuation of Dual Antiplatelet Therapy in High-Risk Patients Requiring Nondeferrable, Non-Cardiac Surgery

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content